Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
Leap crashes as midphase data mark end of gastric cancer program
Leap axed plans to advance into phase 3 in gastric cancer, sending its stock down 60%, but it is forging ahead in another indication.
Nick Paul Taylor
Jan 28, 2025 8:31am
JPM25: Guardant posts 31% sales gain as cancer blood tests grow
Jan 13, 2025 9:19am
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Dec 10, 2024 4:05pm
Guardant awarded $292M in false advertising suit against Natera
Nov 26, 2024 10:45am
Engineered yeast delivers PD-1 inhibitors, shrinks mice tumors
Nov 22, 2024 3:12pm
FDA approves Exact Sciences’ next-gen Cologuard Plus home test
Oct 4, 2024 12:30pm
